Details for New Drug Application (NDA): 091189
✉ Email this page to a colleague
NDA 091189 describes METHAMPHETAMINE HYDROCHLORIDE, which is a drug marketed by Able, Dr Reddys Labs Sa, Hikma, Rexar, and Teva, and is included in five NDAs. It is available from three suppliers. Additional details are available on the METHAMPHETAMINE HYDROCHLORIDE profile page.
The generic ingredient in METHAMPHETAMINE HYDROCHLORIDE is methamphetamine hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the methamphetamine hydrochloride profile page.
The generic ingredient in METHAMPHETAMINE HYDROCHLORIDE is methamphetamine hydrochloride. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the methamphetamine hydrochloride profile page.
Summary for 091189
| Tradename: | METHAMPHETAMINE HYDROCHLORIDE |
| Applicant: | Dr Reddys Labs Sa |
| Ingredient: | methamphetamine hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 091189
| Physiological Effect | Appetite Suppression Central Nervous System Stimulation Increased Sympathetic Activity |
Medical Subject Heading (MeSH) Categories for 091189
Suppliers and Packaging for NDA: 091189
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| METHAMPHETAMINE HYDROCHLORIDE | methamphetamine hydrochloride | TABLET;ORAL | 091189 | ANDA | Mayne Pharma Commercial LLC | 68308-115 | 68308-115-01 | 100 TABLET in 1 BOTTLE, PLASTIC (68308-115-01) |
| METHAMPHETAMINE HYDROCHLORIDE | methamphetamine hydrochloride | TABLET;ORAL | 091189 | ANDA | Dr. Reddy's Laboratories Inc | 75907-094 | 75907-094-01 | 100 TABLET in 1 BOTTLE, PLASTIC (75907-094-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
| Approval Date: | Apr 21, 2010 | TE: | AA | RLD: | No | ||||
Complete Access Available with Subscription
